MENLO PARK, Calif. and BOSTON, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Nick Harvey as Chief Financial Officer. Mr. Harvey will be responsible for leading the company’s financial strategy and management of activities related to accounting, capital markets and business operations.
“We are delighted to welcome Nick to Adicet’s executive leadership team,” said Chen Schor, President and Chief Executive Officer of Adicet. “With his deep business and financial expertise, Nick has demonstrated the ability to successfully guide teams through significant organizational growth throughout his career. His financial, strategic and business insights will undoubtedly add great value to our team, and will be instrumental in our next phase of growth.”
“I am pleased to join Adicet during this pivotal time in the company’s strategic development,” said Nick Harvey, Chief Financial Officer of Adicet Bio, Inc. “Adicet is uniquely positioned to capitalize on the opportunities ahead and I look forward to advancing its financial and business strategy to support its long-term success as we advance our gamma delta T cell platform and programs into the clinic.”
Mr. Harvey has over 20 years of experience in financial operations, capital markets, investor relations and M&A transactions as well as managing corporate growth for life science companies. Mr. Harvey joins Adicet most recently from Centrexion Therapeutics, a privately held biotechnology company, where he served as Executive Vice President and Chief Financial Officer. Previously, he served as the Chief Financial Officer of Radius Health where he helped successfully complete its initial public offering and transition from a research and development stage company to a commercial organization. During his tenure at Radius, he oversaw financial operations, business development, legal, facilities, and information technology. Prior to that, Mr. Harvey served as a Managing Director at Shiprock Capital, a venture capital firm, where he managed investments and development of early and late-stage companies. Mr. Harvey received his MBA from Harvard Business School, and earned both a law degree and an undergraduate degree in Economics from the Australian National University.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.
